Genomic Surveillance Key in Combating Pneumococcal Meningitis

According to a study in The Lancet Microbe, genomic surveillance and broader vaccine targeting are significant factors in improving pneumococcal meningitis outcomes among adult patients.¹

“Genomic surveillance is the monitoring and study of genetic changes and variations in disease-causing organisms like viruses and bacteria,” wrote the authors of a Frontiers in Science report.² “The approach uses next-generation sequencing—now faster and more affordable than ever, thanks to advances in technology—to sequence and analyze the whole genome of a pathogen quickly and accurately.”

By integrating whole genome sequencing with epidemiological data, health professionals can track bacterial evolution, detect emerging drug resistance, and evaluate vaccine effectiveness. This comprehensive molecular tracking provides essential intelligence that allows public health teams to anticipate epidemiological shifts rather than merely reacting to severe outbreaks.

READ MORE: Experts Urge Pneumococcal Vaccination for Older Patients With Chronic Respiratory Disease

For pharmacists, understanding these genomic patterns is vital because Streptococcus pneumoniae remains a primary cause of bacterial meningitis across age groups, causing severe mortality and neurological sequelae. In adults, infection often presents abruptly with a fever, severe headache, and neck stiffness, requiring urgent hospitalization and targeted antibiotic therapy.^1,3,4

Long-Term Insights from Years of Clinical Data

A landmark observational study analyzed 387 adult pneumococcal meningitis cases over 5 decades. The investigation revealed that clinical presentation and mortality vary drastically by infection source.¹

Acute otitis media was the most frequent origin at 45% of cases, dominated by serotype 3 within lineage Global Pneumococcal Sequence Cluster (GPSC) 12, carrying a 10% mortality rate. In contrast, bloodstream dissemination accounted for 27% of cases and resulted in a stark 48% mortality rate, predominantly involving serotype 4.

Infection secondary to cerebrospinal fluid leakage comprised another 27% of cases, affecting younger individuals with a 9% mortality rate and broader lineage diversity.¹

Evolving Threat of Antimicrobial Resistance, Serotype Replacement

Pediatric pneumococcal conjugate vaccines (PCVs) reshaped epidemiological patterns over time, driving significant declines in vaccine targeted serotypes and overall beta lactam resistance. Over 5 decades, penicillin nonsusceptibility dropped from 32% to 20%, while cefotaxime resistance fell from 19% to 6%.

However, persistent lineages like cluster 6 and cluster 16 continue to harbor mobile resistance elements carrying tetM, ermB, and cat genes. Furthermore, nonvaccine serotypes like serotype 8 and serotype 12F have expanded, highlighting the need for broader vaccines such as 20-valent and 21-valent PCV formulations.^1,4

According to the Meningitis Research Foundation, roughly 33% of survivors suffer long-term complications, reinforcing the urgency of expansive immunization strategies.⁴

“Vaccines are available that protect against some of the most common harmful circulating strains of pneumococcal bacteria,” they wrote. “There is no pneumococcal vaccine currently available that will protect against all the different serotypes of pneumococcal bacteria that can cause meningitis, so being aware of the symptoms of the disease remains important.”

Pharmacist Participation in Antimicrobial Stewardship

Translating complex genomic findings into direct care relies on active intervention from clinical pharmacists. A retrospective cohort study evaluating clinical pharmacist participation in neurosurgical infection management demonstrated marked clinical benefits.⁵

Patients receiving pharmacist-led care achieved higher treatment improvement rates and superior antibiotic rationality scores. Antimicrobial stewardship programs led by pharmacists lowered antibiotic use density from 167.68 to 127.63 and reduced unnecessary regimen switching from 50% to 15.1%.

In community settings, pharmacists further strengthen public health by administering vaccines, preventing nasopharyngeal bacterial carriage, and essentially halting transmission across populations.^3,4

“This longitudinal study provides a comprehensive view of adult pneumococcal meningitis over 5 decades, revealing changes in sources of infection, serotype distribution, pneumococcal lineages, and antimicrobial resistance patterns over time,” concluded the authors of the current study.¹ “Lineage-level findings suggested variability in clinical outcomes, underscoring the importance of continued genomic surveillance and supporting consideration of broader vaccine targets.”

READ MORE: Pneumococcal Resource Center

REFERENCES

1. Calvo-Silveria S, González-Díaz A, Cabellos C, et al. Five decades of pneumococcal meningitis in Spain: a single-centre, clinical and genomic, retrospective, observational study. Lancet Microbe. September 1, 2026:101471. doi:10.1016/j.lanmic.2026.101471

2. Struelens MJ, Ludden C, Werner G, et al. Real-time genomic surveillance for enhanced control of infectious diseases and antimicrobial resistance. Front Sci. 2024;2. doi:10.3389/fsci.2024.1298248

3. Meningitis. US Pharmacist. September 27, 2018. Accessed September 15, 2026. https://www.uspharmacist.com/article/meningitis-1

4. Pneumococcal meningitis. Meningitis Research Foundation. December 16, 2024. Accessed September 15, 2026. https://www.meningitis.org/about-meningitis/bacterial-meningitis/pneumococcal-meningitis/

5. Cheng J, Dang C, Li X, et al. The participation of clinical pharmacists in the treatment of patients with central nervous system infection can improve the effectiveness and appropriateness of anti-infective treatments: a retrospective cohort study. Front Pharmacol. 2023 Sep 7;14:1226333. doi: 10.3389/fphar.2023.1226333